In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Carolina BioPharm Inc.

Latest From Carolina BioPharm Inc.

Carolina BioPharm Inc.

Scientists are now recognizing that many kinds of cancers are able to build their own blood-supply systems even in the presence of anti-angiogenic drugs including antibodies and tailored chemicals. While no one can say for sure just what enables "angiogenic escape" and "vascular mimicry" by cancers, researchers are pursuing clues - and some companies are working to develop new drugs based on their findings. For its part, Carolina BioPharm believes that the small peptide it currently has in Phase IIa trials will prove to be a better angiogenesis inhibitor than Avastin and its ilk, because it inhibits not only VEGF but also placental growth factor (PlGF).

Start-Up Previews (10/2010)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Eyeing New Drugs For Glaucoma," features profiles of Altheos, Amakem and Mimetogen Pharmaceuticals. Plus these Start-Ups Across Health Care: Aragon Surgical, Arcarios, Carolina BioPharm, Miromatrix Medical and Pathogenica.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Carolina BioPharm Inc.
  • Senior Management
  • Stephen Elliston, Pres. & CEO
  • Contact Info
  • Carolina BioPharm Inc.
    Phone: (919) 845-9695
    5808 Rocky Point Ct.
    Raleigh, NC 27613